Preparation of aβ1-40 or aβ1-42 recombinant antibody and its application in alzheimer's disease combined detection kit
By preparing recombinant antibodies of Aβ1-40 or Aβ1-42, the problem of insufficient antibody preparation in existing technologies has been solved, realizing an efficient and stable blood testing method suitable for early screening of Alzheimer's disease.
CN120699146BActive Publication Date: 2026-06-05SHANDONG LIFEI BIOLOGICAL IND CO LTD
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SHANDONG LIFEI BIOLOGICAL IND CO LTD
- Filing Date
- 2025-06-11
- Publication Date
- 2026-06-05
Smart Images
Figure CN120699146B_ABST
Abstract
The application provides a preparation of A beta 1-40 or A beta 1-42 recombinant antibody and application thereof in an Alzheimer's disease combined detection kit, belongs to the technical field of Alzheimer's disease detection, and comprises screening specific antibodies for A beta 1-40 and A beta 1-42 proteins, and successfully expressing the recombinant anti-A beta 1-40 and A beta 1-42 antibodies with high affinity by using HEK293 cells. The A beta 1-40 and A beta 1-42 combined detection kit is prepared, a combined detection method for detecting the A beta 1-40 and A beta 1-42 levels in serum is established by using a flow fluorescence technology and a double-antibody sandwich method, and the combined detection method has important application value and significance for a large-scale early screening of AD.
Need to check novelty before this filing date? Find Prior Art